SMITH & NEPHEW PLC
307 institutions still hold SMITH & NEPHEW PLC as of Q2 2026. Tracked across SEC 13F-HR filings, with insider and 13D/G activity surfaced alongside.
Smith & Nephew plc (SNN, CUSIP 83175M205) entered Q1 2026 with $900M of institutional 13F value across 263 holders — a holder profile appropriate for a global medical-device and orthopaedics company whose primary franchises span hip and knee replacement, sports medicine, trauma, and advanced wound-management products, with institutional interest concentrated among healthcare-device and European-equity managers rather than diversified large-cap U.S. strategies. The defining Q1 signals: Todd Asset Management added $13M and Bank of Montreal reduced $35M in what represents routine rotation within the healthcare-device sleeve rather than a thesis-revision event. With 2 new positions in a relatively compact holder universe, the stock's institutional base is slowly expanding as European and global-device managers build positions at the margin. For smart-money trackers, SNN is most informative at the healthcare-device-sector tier rather than as a single-name conviction story — the orthopaedics market is mature with predictable replacement demand driven by aging demographics, and institutional flows into SNN track healthcare-device-sector allocation decisions.
Top holders
Sorted by position value. Source: SEC EDGAR 13F-HR filings.